Search
Browse
Statistics
Feeds

Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire

[thumbnail of Original Article]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB
[thumbnail of Supplemental Material]
Preview
PDF (Supplemental Material) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
591kB

Item Type:Article
Title:Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire
Creators: Rosenberger, L., Hansmann, L. ORCID logoORCID: https://orcid.org/0000-0003-3790-0128, Anastasopoulou, V., Wolf, S.P. ORCID logoORCID: https://orcid.org/0009-0008-2723-695X, Drousch, K., Moewes, C., Feng, X., Cao, G., Huang, J. ORCID logoORCID: https://orcid.org/0000-0003-0271-4384, Yew, P.Y., Strønen, E. ORCID logoORCID: https://orcid.org/0000-0001-9314-9389, Kato, T., Saligrama, N., Olweus, J., Nakamura, Y., Willimsky, G. ORCID logoORCID: https://orcid.org/0000-0002-9693-948X, Blankenstein, T. ORCID logoORCID: https://orcid.org/0000-0002-3357-4321, Schreiber, H. and Leisegang, M. ORCID logoORCID: https://orcid.org/0000-0003-3692-7142
Abstract:BACKGROUND: The development of T-cell receptor (TCR)-based T-cell therapies is hampered by the difficulties in identifying therapeutically effective tumor-specific TCRs from the natural repertoire of a patient's cancer-specific T cells. METHODS: Here, we mimic experimentally near-patient conditions to analyze the T-cell repertoire in euthymic tumor-bearing mice responding to the H-2K(b)-presented neoantigen p68(S551F) (mp68). We temporarily separated the time point of mp68 expression from that of cancer cell transplantation to exclude the influence of injection-induced inflammation on T-cell priming. Thus, the mp68-specific T-cell response could only develop after the acute inflammatory phase had subsided.Here, we mimic experimentally near-patient conditions to analyze the T-cell repertoire in euthymic tumor-bearing mice responding to the H-2K(b)-presented neoantigen p68(S551F) (mp68). We temporarily separated the time point of mp68 expression from that of cancer cell transplantation to exclude the influence of injection-induced inflammation on T-cell priming. Thus, the mp68-specific T-cell response could only develop after the acute inflammatory phase had subsided. RESULTS: We found that mp68-specific TCRs isolated from either tumor-infiltrating T cells or spleens of mice immunized with mp68-expressing cancer cells are diverse and not inherently therapeutic when introduced into peripheral T cells and used for adoptive therapy of established tumors. While measuring short-term T-cell responses in vitro was unreliable for some TCRs in predicting their therapeutic failure, assessing the persistence of cancer cell destruction by TCR-modified T cells in long-term cultures accurately predicted therapeutic outcomes. A tumor-derived TCR with optimal function was also correctly identified with this approach when analyzing human TCRs that recognize the HLA-A2-presented neoantigen CDK4(R24L). CONCLUSIONS: We show that a neoantigen-directed T-cell response in tumor-bearing hosts comprises a diverse repertoire. Infiltration and expansion of certain T-cell clonotypes in the tumor do not necessarily correlate with therapeutic efficacy of their TCRs in adoptive therapy. We propose that analysis of persistent rather than immediate responses of TCR-modified T cells in vitro serves as a reliable parameter to identify TCRs that are therapeutically effective in vivo.
Keywords:Adoptive Immunotherapy, Neoplasm Antigens, Neoplasms, T-Cell Antigen Receptors, T-Lymphocytes, Tumor Cell Line, Animals, Mice
Source:Journal for ImmunoTherapy of Cancer
ISSN:2051-1426
Publisher:BMJ Publishing Group
Volume:13
Number:5
Page Range:e011351
Date:2 May 2025
Official Publication:https://doi.org/10.1136/jitc-2024-011351
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library